ProMIS Neurosciences Inc. (NASDAQ:PMN) rose 6% on Monday after new research findings bolstered confidence in the company’s ...

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive degradation of brain cells, as well ...

Alzheimer’s disease is the most commonly diagnosed form of dementia, but it’s far from the only one. In fact, most people who ...

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

The test confirms the scientific validity of the biomarkers used in the lab, led by researcher Carleara Weiss, and increases ...

Circular Genomics, Inc., the world-leading developer of circular RNA-based precision medicine tools for neurology and ...

Regular physical activity in midlife and older adulthood may cut dementia risk by up to 45%, showing it’s never too late to ...

New research published in the journal Nature suggests that modest doses of lithium orotate may prevent or even reverse ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

As Alzheimer’s Awareness Month comes to an end, Florida State University researchers are continuing efforts to better ...

In people at risk for Alzheimer’s disease, researchers linked minimal to moderate physical activity to a 3-to 7-year delay in cognitive symptoms.

Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...